Dr Lucy Stead
Research profile and key clinical specialties
My group is focused on understanding why glioblastoma (GBM), the most common and most deadly form of adult brain cancer, is currently incurable.
We approach this by molecularly profiling pairs of primary and post-treatment recurrent GBM tumours to identify and characterise the cells that inevitably survive after first line treatment, and learn how we can more effectively kill them.
The group is hybrid as it consists of both computational and experimental biologists.
We use patient tissue to generate hypotheses and adopt a variety of clinical models in order to test them.
Two key publications
- Floris Barthel et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019; 576:112-120. PMID: 31748746
- Nora Rippaus, Alexander F-Bruns, Georgette Tanner, Claire Taylor, Alastair Droop, Anke Brüning-Richardson, View ORCID ProfileMatthew A. Care, Joseph Wilkinson, Michael D. Jenkinson, Andrew Brodbelt, Aruna Chakrabarty, Azzam Ismail, Susan Short, Lucy F. Stead. JARID2 facilitates transcriptional reprogramming in glioblastoma in response to standard treatment. bioRXiv doi: https://doi.org/10.1101/649400
Possible PhD projects
- Exploiting a GBM-on-chip ex vivo preclinical model to characterise epigenetic reprogramming within GBM tumours during standard treatment
I was awarded a UKRI Future Leaders Fellowship in 2020, based on the work in the preprint above, which we decided to use to expand that body of work prior to full publication. I am on the Scientific Advisory Board for The Brain Tumour Charity.
Keywords: Glioblastoma, GBM, Tumours, Brain, Cancer, Lucy, Stead, Leeds